ASCO Annual Meeting | Conference

Avelumab Controls hCG Levels Lead to Remissions in Gestational Trophoblastic Tumors

May 29th 2020

Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.

Adjuvant Osimertinib Significantly Improves DFS in Early-Stage EGFR+ NSCLC

May 29th 2020

Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.

Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma

May 29th 2020

Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.

Pembrolizumab Doubles PFS in Newly Diagnosed MSI-H/dMMR mCRC

May 29th 2020

Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.

Active Cancer Strongly Associated With Increased COVID-19 Mortality

May 29th 2020

An analysis of data collected in the COVID-19 and Cancer Consortium registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 compared with patients in remission or with no evidence of disease.

Dr. You on Findings from the TROPHIMMUN Study in Gestational Trophoblastic Tumors

May 29th 2020

Benoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.

Dr. Powles on Maintenance Avelumab in Urothelial Carcinoma

May 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the utility of maintenance avelumab in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.

ASCO 2020: Oncology Experts Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

We spoke with leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their specialties.

ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 14th 2020

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Cancer Mortality Rate Declined More Steeply in States That Expanded Medicaid Under the Affordable Care Act

May 14th 2020

The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t following the passage of the Affordable Care Act of 2010, a study found.

Video Conference Visits Effective in Reducing Stress, Anxiety in Caregivers for Patients with Cancer

May 14th 2020

The use of video conference technology significantly reduced anxiety and stress among individuals who provide care for an individual with cancer and live more than one hour away from the patient.

Integrated Geriatric Assessment Optimizes Care for Older Adults with Cancer

May 13th 2020

Integration of a comprehensive geriatric assessment with geriatrician-led management care improved health-related quality of life, unplanned hospital admissions, and treatment discontinuation among older adults undergoing systemic therapy for their cancer.

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 13th 2020

Maintenance Therapy with Olaparib Extends Survival in Relapsed, BRCA+ Ovarian Cancer

May 13th 2020

Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.

Larotrectinib Effective in TRK+ Pediatric Cancers and CNS Tumors

June 7th 2019

The efficacy of larotrectinib is supported in distinct patient populations with TRK fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.

Neratinib Combo Improves PFS in HER2+ Breast Cancer

June 6th 2019

Neratinib combined with capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who received at least 2 prior lines of HER2-targeted therapy.

Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer

June 5th 2019

Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.

Margetuximab Superior to Trastuzumab on PFS in HER2-Positive Metastatic Breast Cancer Carriers of CD16A-F Allele

June 5th 2019

Margetuximab, a novel Fc-engineered HER2-targeted antibody, improved progression-free survival compared with trastuzumab in patients with pretreated HER2-positive metastatic breast cancer in the open-label phase III SOPHIA clinical trial.

Acalabrutinib Combo Induces High Responses in CLL

June 5th 2019

Simultaneous targeting of Bruton’s tyrosine kinase and the CD20 antigen led to overall responses in more than 90% of patients with chronic lymphocytic leukemia, including untreated and relapsed/refractory disease.